Company Filing History:
1 out of 377 
1 out of 1,743 
Years Active: 2009
Title: The Innovations of Hong Zheng
Introduction
Hong Zheng is a notable inventor based in Strasbourg, France. He has made significant contributions to the field of biotechnology, particularly in the regulation of angiogenic factors. His work has implications for therapeutic applications, showcasing the intersection of science and innovation.
Latest Patents
Hong Zheng holds a patent titled "Net, a transcription factor of the TCF family, as regulator of angiogenic factor expression." This invention relates to the regulation of the activity of the NET (ERP/SAP-2) protein and compounds that modify or regulate NET protein activity. The patent also includes methods for screening agonists or antagonists of NET to identify new pro-angiogenic or anti-angiogenic compounds. Furthermore, it discusses the use of transgenic animals bearing mutations in the NET gene, highlighting the potential for groundbreaking therapeutic uses.
Career Highlights
Throughout his career, Hong Zheng has worked with prominent organizations such as Aventis Pharma S.A. and the Institut National de la Santé et de la Recherche Médicale. His experience in these institutions has allowed him to advance his research and contribute to significant scientific advancements.
Collaborations
Hong Zheng has collaborated with esteemed colleagues, including Bohdan Wasylyk and Marie-Christine Multon. These partnerships have enriched his research and expanded the impact of his innovations.
Conclusion
Hong Zheng's contributions to biotechnology and his innovative patent demonstrate his commitment to advancing scientific knowledge and therapeutic applications. His work continues to inspire future research in the field.